Evidence map›Paper›PMID 38800555›Full record

ArticleClinical & translational immunology2024

Engineered CAR-T cells targeting the non-functional P2X purinoceptor 7 (P2X7) receptor as a novel treatment for ovarian cancer.

Veronika Bandara, Victoria M Niktaras, Vasiliki J Willett, Hayley Chapman, Noor A Lokman, Anne M Macpherson, Silvana Napoli, Batjargal Gundsambuu, Jade Foeng, Timothy J Sadlon and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & translational immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Role of P2X7R in Retinal Diseases: A Review.Immunity, inflammation and disease · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Veronika BandaraMolecular Immunology, Robinson Research Institute University of Adelaide Adelaide SA Australia.
Victoria M NiktarasReproductive Cancer Research Group, Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute University of Adelaide Adelaide SA Australia.
Vasiliki J WillettReproductive Cancer Research Group, Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute University of Adelaide Adelaide SA Australia.
Hayley ChapmanReproductive Cancer Research Group, Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute University of Adelaide Adelaide SA Australia.
Noor A LokmanReproductive Cancer Research Group, Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute University of Adelaide Adelaide SA Australia.
Anne M MacphersonReproductive Cancer Research Group, Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute University of Adelaide Adelaide SA Australia.
Silvana NapoliMolecular Immunology, Robinson Research Institute University of Adelaide Adelaide SA Australia.
Batjargal GundsambuuMolecular Immunology, Robinson Research Institute University of Adelaide Adelaide SA Australia.
Jade FoengChemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Sciences The University of Adelaide Adelaide SA Australia.
Timothy J SadlonMolecular Immunology, Robinson Research Institute University of Adelaide Adelaide SA Australia.
Justin CoombsCarina Biotech, Level 2 Innovation & Collaboration Centre Adelaide SA Australia.
Shaun R McCollChemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Sciences The University of Adelaide Adelaide SA Australia.
Simon C BarryMolecular Immunology, Robinson Research Institute University of Adelaide Adelaide SA Australia.
Martin K OehlerReproductive Cancer Research Group, Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute University of Adelaide Adelaide SA Australia.
Carmela RicciardelliReproductive Cancer Research Group, Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute University of Adelaide Adelaide SA Australia.ORCID https://orcid.org/0000-0001-7415-1854

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Recent studies have identified expression of the non-functional P2X7 (nfP2X7) receptor on various malignant cells including ovarian cancer, but not on normal cells, which makes it a promising tumour-associated antigen candidate for chimeric antigen receptor (CAR)-T-cell immunotherapies. In this study, we assessed the cytotoxic effects of nfP2X7-CAR-T cells on ovarian cancer using Methods: We evaluated the effects of nfP2X7-CAR-T cells on ovarian cancer cell lines (SKOV-3, OVCAR3, OVCAR5), normal peritoneal cells (LP-9) and primary serous ovarian cancer cells derived from patient ascites Results: Our study found that nfP2X7-CAR-T cells were cytotoxic and significantly inhibited survival of OVCAR3, OVCAR5 and primary serous ovarian cancer cells compared with un-transduced CD3 Conclusion: This study demonstrates that nfP2X7-CAR-T cells have great potential to be developed as a novel immunotherapy for ovarian cancer.

Indexed as

3D‐spheroidCAR‐T cellsexplant assaysimmunotherapyin vivoovarian cancer

Identifiers

PMID38800555
PMCPMC11116765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.